- Home
- ACLX vs ADMA Comparison
ACLX vs ADMA Comparison
Compare ACLX & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLX
- ADMA
- Stock Information
- Founded
- ACLX 2015
- ADMA 2004
- Country
- ACLX United States
- ADMA United States
- Employees
- ACLX N/A
- ADMA N/A
- Industry
- ACLX Biotechnology: Pharmaceutical Preparations
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACLX Health Care
- ADMA Health Care
- Exchange
- ACLX Nasdaq
- ADMA Nasdaq
- Market Cap
- ACLX 5.3B
- ADMA 4.1B
- IPO Year
- ACLX 2022
- ADMA N/A
- Fundamental
- Price
- ACLX $78.90
- ADMA $17.60
- Analyst Decision
- ACLX Strong Buy
- ADMA Strong Buy
- Analyst Count
- ACLX 14
- ADMA 4
- Target Price
- ACLX $107.67
- ADMA $21.25
- AVG Volume (30 Days)
- ACLX 599.1K
- ADMA 2.7M
- Earning Date
- ACLX 11-07-2024
- ADMA 11-07-2024
- Dividend Yield
- ACLX N/A
- ADMA N/A
- EPS Growth
- ACLX N/A
- ADMA N/A
- EPS
- ACLX N/A
- ADMA 0.28
- Revenue
- ACLX $155,818,000.00
- ADMA $382,809,000.00
- Revenue This Year
- ACLX $12.58
- ADMA $66.84
- Revenue Next Year
- ACLX N/A
- ADMA $14.72
- P/E Ratio
- ACLX N/A
- ADMA $62.11
- Revenue Growth
- ACLX 230.33
- ADMA 63.39
- 52 Week Low
- ACLX $47.88
- ADMA $4.27
- 52 Week High
- ACLX $107.37
- ADMA $23.64
- Technical
- Relative Strength Index (RSI)
- ACLX 40.06
- ADMA 37.86
- Support Level
- ACLX $73.39
- ADMA $17.08
- Resistance Level
- ACLX $90.23
- ADMA $18.97
- Average True Range (ATR)
- ACLX 4.31
- ADMA 0.71
- MACD
- ACLX -0.60
- ADMA -0.23
- Stochastic Oscillator
- ACLX 27.75
- ADMA 10.36
About ACLX Arcellx Inc.
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.